CD63 molecule
CD63 molecule is a member of the tetraspanin family of membrane proteins and is widely used as a canonical marker of extracellular vesicles, especially exosomes.
CD63 molecule is a member of the tetraspanin family of membrane proteins and is widely used as a canonical marker of extracellular vesicles, especially exosomes. In biomedical research, CD63 is commonly detected alongside other EV-associated proteins such as CD81, ALIX, HSP70/90, Syntenin-1, and Annexin A2 to support vesicle identity and assess preparation quality. Because it is enriched on small vesicles released by many cell types, CD63 is frequently used in exosome isolation, characterization, and capture platforms.
Functionally, CD63 is important less as a disease-specific biomarker than as a practical surface target for EV detection and enrichment. Recent studies have used CD63 aptamers, antibody-based assays, and dual-marker strategies to improve the capture of tumor-derived exosomes and other EV populations. In these settings, CD63 serves as a stable membrane handle for analytical platforms aimed at liver cancer biomarkers, colorectal cancer residual disease, spinal cord injury-related vesicles, and engineered therapeutic exosomes.
Rebuilt from PubMed 1 Sept 2026 · no new papers today
Where the papers sit
8 papers study cd63 molecule directly. Those 8 are one subject: Exosome Profiling and Therapy. Exosome research is moving toward multiplexed, subpopulation-specific detection, with nanozymes, CRISPR/Cas12a, DNA scaffolds and magnetic isolation supporting cancer monitoring. Therapeutic exosomes are also being developed to restore mitochondrial and synaptic function. No way of splitting those 8 scores better than chance.
Recent Findings on CD63 molecule
Recent studies converge on CD63-centered extracellular vesicle capture and phenotyping as a basis for sensitive, increasingly multiplexed detection. Aptamer-functionalized platforms using nanozymes, DNA tetrahedrons, and engineered microspheres achieved broad quantitative ranges or low detection limits, while multimodal readouts—including colorimetric/photothermal, SERS/electrochemical, and machine-learning–assisted analyses—were designed to reduce matrix interference and signal variability 42507175Jul42296185Jun42190059May. These approaches differentiated cancer-associated vesicles from controls in preliminary serum or plasma cohorts, although their analytical performance and target specificity varied by platform; some assays measured CD63-positive vesicle abundance, whereas others added markers such as HER2, MUC1, PD-L1, or AFP for phenotyping. Clinical relevance is also being explored through CD9/CD63-positive vesicles, which decreased after colorectal tumor resection and were proposed as potential indicators of residual tumor 42049365Apr.
Work on tumor exosome diagnostics is moving from generic vesicle measurement toward selective isolation and analysis of tumor-associated subpopulations and their molecular cargo. CD63-targeted aptamers supported rapid, high-purity exosome enrichment for downstream proteomic profiling, while other systems combined CD63 recognition with PD-L1 or subpopulation-specific capture to detect exosomal RNA or microRNA in situ 42067286May42231680Jun42025056Apr. These platforms enabled disease or treatment-related discrimination in experimental models and clinical samples, including monitoring tumor progression and distinguishing therapeutic responses, but their results emphasize biological heterogeneity rather than a uniform CD63 signature. In particular, MUC1-positive vesicles produced higher diagnostic Area Under the Curve values for miR-21 and miR-155 than CD63-positive vesicles, indicating that CD63 is useful as a capture marker but may not provide the most informative diagnostic subpopulation on its own 42025056Apr.
Human induced pluripotent stem cell-derived exosomes are being investigated as a cell-free approach to Huntington’s disease, with CD63 serving among the canonical markers used to characterize the vesicles. In Huntington’s disease neural stem cells, treatment with these exosomes reduced mutant huntingtin aggregation, restored mitochondrial membrane potential and morphology, promoted neurite outgrowth and synaptic maturation, and shifted signaling toward neuronal survival by increasing BCL-2 and TrkB while reducing BAX, cleaved Caspase-3, NF-κB, and JNK 41846052Mar. The findings support a multimodal mitochondrial, synaptic, anti-apoptotic, and anti-inflammatory mechanism, but the reported evidence is limited to cellular treatment experiments and does not establish clinical therapeutic efficacy.
Written from 8 PubMed abstracts, each one cited by PMID above. Published: 2026-07-08. Last written: 2026-08-27 by GPT. Drafted by language models from published abstracts; not medical advice.